7548 Background: Patients with stage III NSCLC are potentially curable using combined
modality therapy (CMT) with chemotherapy and radical radiation (RT). The use of PET-CT …

7018 Background: Patients with stage 3 NSCLC are potentially curable using combined
modality therapy (CMT) with chemotherapy and radical radiation therapy (RT). PET/CT …

We investigated the incremental management impact and prognostic value of staging with
18F-FDG PET/CT in patients with non–small cell lung cancer (NSCLC) being considered for …

Purpose Positron emission tomography (PET) is a costly new technology with potential to
improve preoperative evaluation for patients with non–small-cell lung cancer (NSCLC) …

Purpose Our objective was to determine the impact of initial 18 F-FDG PET/CT (PET/CT)
staging on clinical stage and the management plan and the prognostic value of PET/CT in …

BACKGROUND AND PURPOSE: To investigate the impact of treatment delays on radiation
therapy (RT) target volumes and overall survival (OS) in patients with non-small cell lung …

Results Three hundred ten patients were randomized: 152 (PET/CT) and 158 (standard CT
planning). One hundred eighteen (78%) of the patients randomized to PET/CT arm received …

Imaging is performed in patients with early stage non-small-cell lung cancer (NSCLC) for
disease staging and to identify the patients most likely to benefit from surgery. Two recent …

Purpose The standard treatment for patients with stage III non-small cell lung cancer
(NSCLC), unsuitable for resection and with good performance, is definitive radiotherapy with …

Background and purpose Pre-and mid-radiotherapy FDG-PET metrics have been proposed
as biomarkers of recurrence and survival in patients treated for stage III non-small cell lung …